do not combine dpp-4 inhibitors with glp-1 receptor agonists guidance DPP4 Inhibitor Mechanism of Action – My Endo Consult SGLT-2 inhibitors, GLP-1 receptor agonists,
Description
Semaglutide , taken weekly: Possibly the most well-known of them all, FDA-approved under the brand names Ozempic for type 2 diabetes and to reduce the risk of a major adverse cardiovascular event in adults with type 2 diabetes or an established cardiovascular disease and Wegovy for obesity

As a result, GLP-1RAs display suppressive effects on mitochondrial functions and oxidative stress on heart failure [79]

PMID: 54 LinLCChenJYHuangTTMWuVC

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial

The evidence is promising, but its not a TikTok miracle
00174-1/asset/4ff9bb50-3a8f-4946-a683-db1579705072/main.assets/gr1.jpg)
Graphical abstract Table 1
